Form Bio Co. Ltd. (377220) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Form Bio Co. Ltd. stock KRW 3,207, price KRW 1,480, upside +116.7%, quality 39 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 1,480 KRW – 49,625 KRW · fair‑value band 2,393 KRW – 4,786 KRW · the 1,480 KRW price screens below the 3,207 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Form Bio Co. in your weekly email
Every Wednesday you see whether Form Bio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
From Bio Co.,Ltd manufactures and sells health related products in South Korea. It offers health functional food, health beauty, and living health products. The company also provides cosmetic products under the Mastina and HYCL brands.
Show moreShow less
In addition, it operates an online platform to retail its products. The company was founded in 2006 and is headquartered in Suwon-si, South Korea.
Stock analysis
Form Bio Co. Ltd. (377220) currently trades at 1,480 KRW, while our model-based Fair Value estimate is 3,207 KRW, implying the stock looks roughly 54% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 90/100, which puts the data coverage at low.
Scenario range: 2,393 KRW (bear) to 4,786 KRW (bull), the price of 1,480 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Form Bio Co. Ltd. reported revenue of 72.2B KRW in FY2025 versus 135B KRW in FY2021, a compound −14.5%/yr. Reported net income was −22.5B KRW in FY2025.
Key figures
Market cap 10.7B KRW (≈ $7.9M) Micro · P/S ratio 0.15 · EPS (TTM) −3,556 KRW · Net margin −28.1% · Return on equity −65.3% · Return on assets (EBIT) −12.4% · Operating margin −3.8% · Revenue (TTM) 71.6B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 7 out of 100 (medium confidence).
What moves the price
The share trades about 82% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −2% fair-value upside, at 117%, 377220 screens cheaper than that median.
Fair Value models
Bear2,393 KRWFair Value 3,207 KRWBull4,786 KRW
Price 1,480 KRW · Upside +116.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+7.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.8%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
18.5% (2020) → −25.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 627 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside+116.7% · Top 25%
Profitability
Return on assets−34.4% · Bottom 25%
Net margin (12 months)−28.1% · Bottom 25%
Operating margin (12 months)−3.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−7.5% · Bottom 25%
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Form Bio Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/377220
Frequently asked questions
Is Form Bio Co. Ltd. (377220) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 3,207 KRW versus a price of 1,480 KRW, about +117% upside (undervalued).
What is the fair value of 377220?
Our model-based fair value for Form Bio Co. Ltd. is 3,207 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 1,480 KRW.
What is the quality score of 377220?
Form Bio Co. Ltd. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Form Bio Co. Ltd. (377220)?
Our model-based price target is the fair value of 3,207 KRW (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 2,393 KRW, optimistic scenario 4,786 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Form Bio Co. Ltd. stock forecast for 2026?
Our models put fair value at 3,207 KRW, about +117% upside versus a price of 1,480 KRW (undervalued). Cautious scenario 2,393 KRW, optimistic scenario 4,786 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Form Bio Co. Ltd. (377220)?
Form Bio Co. Ltd. reported trailing-twelve-month revenue of about 71.6B KRW (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Form Bio Co. Ltd. (377220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Form Bio Co. Ltd. it is 3,207 KRW per share (as of Nov 4, 2026), against a price of 1,480 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Form Bio Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 377220 trades below its calculated fair value: price 1,480 KRW, fair value 3,207 KRW, a gap of about +117% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 377220?
No. The price is what the market pays today (1,480 KRW); the fair value is what the company's own numbers justify (3,207 KRW). For Form Bio Co. Ltd. the two are 1,727 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Form Bio Co. Ltd. worth?
The market values Form Bio Co. Ltd. at about 10.7B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 1,480 KRW; our models calculate a fair value of 3,207 KRW per share.
What do the bullish and bearish scenarios say about 377220?
Our models span a range for Form Bio Co. Ltd.: cautious scenario 2,393 KRW, base 3,207 KRW, optimistic 4,786 KRW per share (as of Nov 4, 2026, price 1,480 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Form Bio Co. Ltd. (377220)?
Balance-sheet figures for Form Bio Co. Ltd. (as of Nov 4, 2026): return on equity −65.3%, debt of 0.05 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 377220 from its 52-week high?
Form Bio Co. Ltd. trades at 1,480 KRW, about 82% below its 52-week high of 8,400 KRW and at the low of 1,480 KRW (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of 3,207 KRW is for.
Which stocks are comparable to Form Bio Co. Ltd.?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Form Bio Co. Ltd. stock attractive at the current price?
The data as of Nov 4, 2026: price 1,480 KRW, calculated fair value 3,207 KRW (+117%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 377220 calculated?
We run Form Bio Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,207 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0% above its aggregate fair value. Form Bio Co. Ltd. currently trades 54% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Form Bio Co. Ltd. (377220)?
The closing price on Nov 4, 2026 was 1,480 KRW. Our model-based fair value is 3,207 KRW, about +117% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Form Bio Co. Ltd. right now?
The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (2,393 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,393 KRW to 4,786 KRW) leaves room in how you read the outcome.
Key figures of Form Bio Co. Ltd.
How large is the market capitalisation of Form Bio Co. Ltd. (377220)?
The market capitalisation of Form Bio Co. Ltd. is 10.7B KRW (≈ $7.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Form Bio Co. Ltd. (377220)?
The price-to-sales ratio of Form Bio Co. Ltd. is 0.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Form Bio Co. Ltd. (377220)?
Earnings per share at Form Bio Co. Ltd. are −3,556 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Form Bio Co. Ltd. (377220)?
The net margin of Form Bio Co. Ltd. is −28.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Form Bio Co. Ltd. (377220)?
The return on equity (ROE) of Form Bio Co. Ltd. is −65.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Form Bio Co. Ltd. (377220)?
On an EBIT basis the return on assets of Form Bio Co. Ltd. is −12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Form Bio Co. Ltd. (377220)?
The operating margin of Form Bio Co. Ltd. is −3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Form Bio Co. Ltd. (377220)?
Revenue at Form Bio Co. Ltd. is growing −7.5% versus a year earlier (3y avg −10.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Form Bio Co. Ltd. (377220) generate?
The free cash flow of Form Bio Co. Ltd. is −11.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Form Bio Co. Ltd. (377220) carry?
The net debt of Form Bio Co. Ltd. is 32.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Form Bio Co. Ltd. in the live analysis
One click puts Form Bio Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026